Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Infections, Pneumonia, Immune System Diseases, STAT3 Transcription Factor, Job Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Cell Tumors, Ocular Medulloepithelioma, Nasal Chondromesenchymal Hamartoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 99 Years
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 2
States / cities: Bethesda, Maryland • Rockville, Maryland

Conditions: Cirrhosis, Decision Support Systems, Clinical
Interventions: CirrhosisRx CDS; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nasal Polyps
Interventions: GSK5784283, Placebo, Standard of Care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Louisville, Kentucky • Tulsa, Oklahoma + 1 more

Conditions: NAFLD, MASLD
Interventions: E-trigger; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis
Interventions: NLY01, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Kansas City, Kansas • Baltimore, Maryland • New York, New York

Conditions: Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Lymphangioleiomyomatosis
Interventions: albuterol inhaler, albuterol nebulizer, PFT; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PF-08046876, Pembrolizumab, Cisplatin, Carboplatin; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 11 more

Conditions: Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Interventions: Minuteman G5 Device; Device
Lead sponsor: Spinal Simplicity LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Newnan, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 4 more

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm; Combination Product
Lead sponsor: Ascendis Pharma Bone Diseases A/S; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Greeley, Colorado • Chicago, Illinois • Minneota, Minnesota + 6 more

Conditions: Polymyalgia Rheumatica (PMR)
Interventions: Movement Pattern Training (MoveTrain), Usual Care; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Recruiting clinical trials

Filter and sort this status page

Live official records

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

CirrhosisRx CDS System

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NAFLD Clinical Care Pathway

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

Natural History Study of Patients With Excess Androgen

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica